Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 22

Trial Status

Completed1
Other1

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT06243458Phase 2Active Not Recruiting
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Low Risk Myelodysplastic Syndromes
PrincipalinvestigatorStart date: 2024-09-10
NCT03824080Phase 2Completed
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
Acute Myeloid LeukemiaHigh-risk Myelodysplastic SyndromeLow-risk Myelodysplastic Syndrome
PrincipalinvestigatorStart date: 2018-12-20

Research Network

Collaboration Network

5 collaborators·10 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Krzysztof Mądry, Dr.

Medical University of Warsaw

Related
1 trials

Shared therapeutic areas:

Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes

Worked with same sponsors:

European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%

Lionel Adès, Prof.

Service d'hématologie seniors Hôpital Saint-Louis, Paris

Related
1 trials

Shared therapeutic areas:

Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes

Worked with same sponsors:

European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%

Valeria Santini, Prof.

University of Careggi, Italy

Related
1 trials

Shared therapeutic areas:

Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes

Worked with same sponsors:

European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%

Diez Campelo, Dr.

University of Salamanca

Related
1 trials

Shared therapeutic areas:

Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes

Worked with same sponsors:

European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%

Yifan Zhai, MD, PhD

Ascentage Pharma Group Inc.

Related
14 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteHigh-risk Myelodysplastic Syndrome
Similarity Score12%

Beata Holkova, MD

Massey Cancer Center

Related
3 trials

Shared therapeutic areas:

Leukemia, Myeloid, Acute
Similarity Score6%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Leukemia, Myeloid, Acute
Similarity Score6%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Myeloid, Acute
Similarity Score6%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Leukemia, Myeloid, Acute
Similarity Score6%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, Acute
Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT06243458Phase 2PrincipalInvestigator

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Low Risk Myelodysplastic Syndromes
Active Not Recruiting
NCT03824080Phase 2PrincipalInvestigator

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Acute Myeloid LeukemiaHigh-risk Myelodysplastic SyndromeLow-risk Myelodysplastic Syndrome
Completed

All 2 trials loaded